ClinicalTrials.gg
Active, not recruitingNCT06533059Updated Jul 15, 2026

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

A Phase 1 interventional study of ALTA2618 in Cancer, Breast Cancer and Endometrial Cancer, sponsored by Alterome Therapeutics, Inc.. Active, not recruiting at 31 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Alterome Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Read the detailed description

This is an open-label, multicenter, Phase 1/1b study of ALTA2618, a mutant-selective and orally bioavailable AKT1 E17K inhibitor, in adults with AKT1 E17K-mutant solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity of ALTA2618, and aims to find the best dose. The study consists of two parts: Part 1 - Dose Escalation and Part 1b - Dose Expansion.

02

Conditions studied

  • Cancer
  • Breast Cancer
  • Endometrial Cancer
  • Metastatic Cancer
  • Advanced Solid Tumor

Keywords

  • AKT1 E17K
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • ER positive breast
  • HR positive breast
  • Triple negative breast cancer
  • Gynecologic cancer
  • Gynecologic neoplasm
  • Gynecologic carcinoma
  • Endometrial cancer
  • Endometrial neoplasm
  • Endometrial carcinoma
  • Cervical cancer
  • Cervical neoplasm
  • Cervical carcinoma
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Fallopian cancer
  • Fallopian carcinoma
  • Fallopian neoplasm
  • Prostate cancer
  • Prostate carcinoma
  • Prostate neoplasm
  • Solid tumors
  • AKT mutation
  • Mutant AKT
  • AKT1 mutation
  • AKT mutant
  • AKT1E17K
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 110 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Alterome Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of a solid tumor harboring AKT1 E17K mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test.
  • Unresectable or disease
  • Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage
  • Evaluable or per v1.1
  • (ECOG) performance status of 0 or 1.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with PI3K and/or mTOR inhibitors
  • Patients known to have KRAS, NRAS, HRAS, or BRAF genomic alterations in their tumor
  • Known condition that prohibits ability to swallow or absorb an oral medication

Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    ALTA2618

    ALTA2618 will be administered continuously at a protocol-defined dose based on cohort assignment

    Drug: ALTA2618

Interventions

  • DrugALTA2618

    Oral ALTA2618 tablets will be administered at protocol-defined dose

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of participants that experience treatment-emergent adverse events (TEAEs).

    Time frame: Up to 39 months

  2. Dose Limiting Toxicities

    Number of participants with Dose Limiting Toxicities (DLTs).

    Time frame: 21 days

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Cmax

    Time frame: Cycle 1 (each cycle is 21 days) Day 1 (or Lead-in) and Day 8: Predose and up to 24 hours postdose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Tmax

    Time frame: Cycle 1 (each cycle is 21 days) Day 1 (or Lead-in) and Day 8: Predose and up to 24 hours postdose

  3. Area Under Plasma Concentration Time Curve During the Dosing Interval (AUCt)

    AUCt

    Time frame: Cycle 1 (each cycle is 21 days) Day 1 (or Lead-in) and Day 8: Predose and up to 24 hours postdose

  4. Terminal Half-Life (t1/2)

    t1/2

    Time frame: Cycle 1 (each cycle is 21 days) Lead-in phase: Predose and up to 72 hours postdose

  5. Overall Response Rate (ORR)

    Assess per RECIST 1.1

    Time frame: Up to 39 months

  6. Duration of Response (DOR)

    Assess per RECIST 1.1

    Time frame: Up to 39 months

  7. Progression-Free Survival (PFS)

    Assess per RECIST 1.1

    Time frame: Up to 39 months

  8. Overall Survival (OS)

    Assess per RECIST 1.1

    Time frame: Up to 39 months

07

Study locations

31 sites
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Denver, Colorado 80218, United States
  • Research Site
    Sarasota, Florida 34232, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site #2
    San Antonio, Texas 78229, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Randwick, New South Wales 2031, Australia
  • Research Site
    Malvern, Victoria 3144, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
  • Research Site
    Caen, 14000, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Kyoto, 606-8507, Japan
  • Research Site
    Tokyo, 135-8550, Japan
  • Research Site
    Seoul, 06591, South Korea
  • Research Site
    Seoul, 13620, South Korea
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08908, Spain
  • Research Site
    Madrid, 28023, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Taipei, 100, Taiwan
  • Research Site
    London, SW3 6JJ, United Kingdom
  • Research Site
    London, W1G 6AD, United Kingdom
  • Research Site
    Manchester, M10 4BX, United Kingdom
  • Research Site
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 28 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Aug 1, 2024
StartActual
Aug 22, 2024
Primary completionEst.
Dec 29, 2026
CompletionEst.
Dec 29, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06533059
Lead sponsor
Alterome Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Aug 22, 2024
Primary completion
Dec 29, 2026 (estimated)
Completion
Dec 29, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Study Medical Director
study director · Alterome Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion